Genetic and therapeutic studies of hemostatic and thrombotic disorders using zebrafish
使用斑马鱼进行止血和血栓性疾病的遗传和治疗研究
基本信息
- 批准号:9894256
- 负责人:
- 金额:$ 78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAnticoagulantsAnticoagulationBiologicalBiological AssayBlood Coagulation DisordersBlood Coagulation FactorChemicalsClustered Regularly Interspaced Short Palindromic RepeatsCoagulation ProcessDiagnosticDiseaseFamilyFishesGeneral PopulationGenesGeneticGenetic studyGenomeHealthHemorrhageHemorrhagic DisordersHemostatic DisordersHemostatic functionHumanIndividualIntravenous infusion proceduresLeadLifeLightMutagenesisOralPathologicPathologyPatientsPenetranceProtein EngineeringRecombinant ProteinsRecombinantsRegulator GenesSeveritiesSeverity of illnessSystemTherapeuticTherapeutic StudiesThrombopoiesisThrombosisWorkZebrafishblood productexperimental studygenetic technologygenome editinghigh riskhuman morbidityhuman mortalityindividualized medicineinnovationmutantnew therapeutic targetnext generation sequencingnovelnovel diagnosticsnovel therapeuticsnucleaseprospectivepublic health relevancetherapeutic targettooltranscription activator-like effector nucleases
项目摘要
PROJECT SUMMARY/ABSTRACT
Pathologic dysregulation of the coagulation system is a major contributor to human morbidity and
mortality, resulting in either excessive bleeding or clotting. Significant progress has been made in the
identification of genetic regulators of the coagulation cascade, but many unknown modifier genes contribute to
the variable disease severity and penetrance observed among patients and families with hemostatic and
thrombotic disorders. Understanding such modifiers could help classify patients at higher risk for pathology as
well as identify novel therapeutic targets. Although major improvements to treatment of hemorrhagic and
bleeding disorders have been made with blood products and human derived or recombinant coagulation
factors, these have limited shelf life and storage conditions, and require intravenous infusion. Anticoagulation
has seen a surge in recent years with many new direct acting oral anticoagulants, but their mechanisms of
action are limited to the coagulation cascade. Building on our previous work, this project will take advantage of
powerful genetic tools, including genome editing nucleases, next generation sequencing, and the zebrafish.
We will conduct a large scale interrogation of the genome to discover hemostasis regulatory genes with the
potential to modify the severity of human coagulation disorders. We have developed a panel of clotting factor
mutant zebrafish using robust genome editing nucleases (TALENS and CRISPR/Cas) and conducted chemical
mutagenesis experiments that have identified potential suppressor mutant lines harboring prospective
thrombosis and hemostasis modifier genes. This panel of mutant fish will also be used for unbiased assays to
identify novel lead molecules that suppress hemorrhage or thrombosis. The approaches described in this
proposal will lead to the identification of the key non-canonical factors regulating hemostasis and
thrombopoiesis, some of which will likely prove to be important genetic modifying factors in humans, or will
suggest novel species-specific but biologically insightful regulatory mechanisms. This will shed light on the
regulatory mechanisms of hemostasis, and the modifiers will also be candidate diagnostic and therapeutic
targets for human thrombotic and hemorrhagic diseases. These targets will be utilized to develop potential
innovative agents and new therapeutic classes for treatment of hemorrhage and thrombosis that could benefit
the general population, as well as patients with bleeding and thrombotic disorders.
项目总结/摘要
凝血系统的病理性失调是导致人类发病率的主要因素,
死亡,导致过度出血或凝血。在以下方面取得了重大进展:
凝血级联的遗传调节因子的鉴定,但许多未知的修饰基因有助于
在患有止血药物的患者和家庭中观察到的不同疾病严重程度和发病率,
血栓性疾病了解这些修饰可以帮助将病理学风险较高的患者分类为
并确定新的治疗靶点。虽然对出血性和
已经用血液制品和人源性或重组凝血剂制造了出血性疾病
由于各种因素,这些药物的保质期和储存条件有限,并且需要静脉输注。抗凝
近年来出现了许多新的直接作用口服抗凝剂的激增,但它们的机制,
作用仅限于凝血级联。在我们以前工作的基础上,该项目将利用
强大的遗传工具,包括基因组编辑核酸酶,下一代测序和斑马鱼。
我们将对基因组进行大规模询问,以发现止血调节基因,
可能改变人类凝血障碍的严重程度。我们研制了一组凝血因子
使用稳健的基因组编辑核酸酶(TALENS和CRISPR/Cas)突变斑马鱼,并进行化学
诱变实验已经鉴定了潜在的抑制突变株系,
血栓形成和止血调节基因。这组突变鱼也将用于无偏测定,
鉴定抑制出血或血栓形成新先导分子。本文中所述的方法
该提案将导致确定调节止血的关键非规范因素,
血小板生成,其中一些可能被证明是人类重要的遗传修饰因子,或将
提出了新的物种特异性但具有生物学洞察力的调节机制。这将有助于阐明
止血的调节机制,并且修饰剂也将是候选的诊断和治疗药物。
人血栓性和出血性疾病的靶点。这些目标将用于开发潜力
治疗出血和血栓形成的创新药物和新的治疗类别,
一般人群以及出血和血栓性疾病患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JORDAN A SHAVIT其他文献
JORDAN A SHAVIT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JORDAN A SHAVIT', 18)}}的其他基金
Genetic and therapeutic studies of hemostatic and thrombotic disorders using zebrafish
使用斑马鱼进行止血和血栓性疾病的遗传和治疗研究
- 批准号:
10115114 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Dissection of the mechanisms underlying sex-influenced cardiovascular disease
剖析性别影响的心血管疾病的潜在机制
- 批准号:
10062572 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Dissection of the mechanisms underlying sex-influenced cardiovascular disease
剖析性别影响的心血管疾病的潜在机制
- 批准号:
10640874 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Dissection of the mechanisms underlying sex-influenced cardiovascular disease
剖析性别影响的心血管疾病的潜在机制
- 批准号:
10407073 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Genetic and therapeutic studies of hemostatic and thrombotic disorders using zebrafish
使用斑马鱼进行止血和血栓性疾病的遗传和治疗研究
- 批准号:
10375366 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Genetic and therapeutic studies of hemostatic and thrombotic disorders using zebrafish
使用斑马鱼进行止血和血栓性疾病的遗传和治疗研究
- 批准号:
10610729 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Dissection of the mechanisms underlying sex-influenced cardiovascular disease
剖析性别影响的心血管疾病的潜在机制
- 批准号:
10240707 - 财政年份:2020
- 资助金额:
$ 78万 - 项目类别:
Dissecting the Genetics of Human Hemostatic Disorders Using Zebrafish
使用斑马鱼剖析人类止血疾病的遗传学
- 批准号:
9243287 - 财政年份:2015
- 资助金额:
$ 78万 - 项目类别:
Dissecting the Genetics of Human Hemostatic Disorders Using Zebrafish
使用斑马鱼剖析人类止血疾病的遗传学
- 批准号:
9032531 - 财政年份:2015
- 资助金额:
$ 78万 - 项目类别:
相似海外基金
EPIphANy (Evaluation of Pharmacological Interactions with Anticoagulants in caNcer patients) program - prostate cancer cohort
EPIPHANy(癌症患者抗凝药理相互作用的评估)计划 - 前列腺癌队列
- 批准号:
479295 - 财政年份:2023
- 资助金额:
$ 78万 - 项目类别:
Operating Grants
Inhibitors of Human Factor XIIIa as New Anticoagulants
人类因子 XIIIa 抑制剂作为新型抗凝剂
- 批准号:
10629057 - 财政年份:2023
- 资助金额:
$ 78万 - 项目类别:
Establishment of comprehensive monitoring of direct oral anticoagulants (DOACs) for clinical application
建立临床应用直接口服抗凝剂(DOAC)综合监测体系
- 批准号:
23K06906 - 财政年份:2023
- 资助金额:
$ 78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interactions of Enzyme-Inducing Antiepileptic Drugs with Direct-Acting Oral Anticoagulants: Risk of Thromboembolic Events
酶诱导抗癫痫药物与直接作用口服抗凝剂的相互作用:血栓栓塞事件的风险
- 批准号:
10605482 - 财政年份:2023
- 资助金额:
$ 78万 - 项目类别:
The Comparative Effectiveness and Safety of Oral Anticoagulants in Patients with Cirrhosis and Atrial Fibrillation
口服抗凝药对肝硬化合并心房颤动患者的有效性和安全性比较
- 批准号:
10559071 - 财政年份:2023
- 资助金额:
$ 78万 - 项目类别:
Search for indicators of blood levels of directly inhibitory oral anticoagulants in coagulation tests using artificial intelligence
使用人工智能在凝血测试中搜索直接抑制性口服抗凝剂的血液水平指标
- 批准号:
22K07388 - 财政年份:2022
- 资助金额:
$ 78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Bleeding on Direct Oral Anticoagulants: Identification of Genetic Risk Factors and a Polygenic Predictive Score in Patients with Atrial Fibrillation
直接口服抗凝剂导致的出血:房颤患者遗传风险因素的鉴定和多基因预测评分
- 批准号:
10536789 - 财政年份:2022
- 资助金额:
$ 78万 - 项目类别:
Study on proper use of oral anticoagulants combined with 5-fluorouracil
口服抗凝药联合5-氟尿嘧啶正确使用研究
- 批准号:
22K06743 - 财政年份:2022
- 资助金额:
$ 78万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Benchmarking a point-of-care test kit for detection of direct-oral anticoagulants
用于检测直接口服抗凝剂的即时检测试剂盒的基准测试
- 批准号:
461790 - 财政年份:2022
- 资助金额:
$ 78万 - 项目类别:
Operating Grants
Direct oral anticoagulants and the risk of colorectal and pancreatic cancers: a population-based cohort study.
直接口服抗凝剂与结直肠癌和胰腺癌的风险:一项基于人群的队列研究。
- 批准号:
474475 - 财政年份:2022
- 资助金额:
$ 78万 - 项目类别:
Studentship Programs